Advertisement

Topics

PubMed Journals Articles About "Cara Therapeutics Trevena Down" RSS

06:25 EDT 26th September 2018 | BioPortfolio

Cara Therapeutics Trevena Down PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Cara Therapeutics Trevena Down articles that have been published worldwide.

More Information about "Cara Therapeutics Trevena Down" on BioPortfolio

We have published hundreds of Cara Therapeutics Trevena Down news stories on BioPortfolio along with dozens of Cara Therapeutics Trevena Down Clinical Trials and PubMed Articles about Cara Therapeutics Trevena Down for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cara Therapeutics Trevena Down Companies in our database. You can also find out about relevant Cara Therapeutics Trevena Down Drugs and Medications on this site too.

Showing "Cara Therapeutics Trevena Down" PubMed Articles 1–25 of 1,400+

PS-CARA: Context-Aware Resource Allocation Scheme for Mobile Public Safety Networks.

The fifth-generation (5G) communications systems are expecting to support users with diverse quality-of-service (QoS) requirements. Beside these requirements, the task with utmost importance is to support the emergency communication services during natural or man-made disasters. Most of the conventional base stations are not properly functional during a disaster situation, so deployment of emergency base stations such as mobile personal cell (mPC) is crucial. An mPC having moving capability can move in the ...


RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but cannot be developed into therapeutics due to challenges in delivering them into the cytoplasm. There is therefore great interest in developing strategies that can enable proteins to enter the cytoplasm of cells. In this review article we will discuss recent progress in intracellular protein therapeutics, which a...


La sarna noruega es una forma especial de escabiosis, infección cutánea producida por el Sarcoptes scabiei, infrecuente y muy contagiosa que afecta principalmente a pacientes inmunodeprimidos, ancianos e institucionalizados.  Se presenta con una erupción eritematosa con costras y placas hiperqueratósicas en manos, pies, cara,  cuero cabelludo  y el tronco. El objetivo del trabajo es mostrar las lesiones cutáneas características de esta patología, su diagnóstico y tratamiento.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. There are limited therapeutic options for children infected with RSV or influenza. This review focuses on therapeutics for RSV and influenza that are currently under clinical investigation.

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development: Preclinical Research.

Eyes on New Product Development.

Eyes on New Product Development.

Topical drug therapeutics for neuropathic pain.

Neuropathic pain (NP) is a particularly severe and intractable chronic condition that is not well treated by commonly recommended systemic pharmacological therapies, partly due to dose-limiting side effects or adverse events. The use of topical therapeutics for NP is growing and benefits from the reduced potential for adverse effects, as well as the ability to directly target peripheral pathological processes. Areas covered: The current review defines and describes the limitations of various commonly prescr...

New Business Models to Accelerate Innovation in Pediatric Oncology Therapeutics: A Review.

Few patient populations are as helpless and in need of advocacy as children with cancer. Pharmaceutical companies have historically faced significant financial disincentives to pursue pediatric oncology therapeutics, including low incidence, high costs of conducting pediatric trials, and a lack of funding for early-stage research.

Critical considerations for immunocapture enrichment LC-MS bioanalysis of protein therapeutics and biomarkers.

In recent years, immunocapture enrichment coupled with LC-MS technology has seen more applications for the measurement of low abundant protein therapeutics and biomarkers in biological matrices. In this article, several critical considerations for the application of immunocapture enrichment to LC-MS bioanalysis of protein therapeutics and biomarkers, including reagent selection, reagent characterization, designing of capture format, etc. are discussed. All these considerations are critical in developing rel...

Characteristics of Infectious Keratitis in Old and Very Old Patients.

The aim of this study was to analyze patient backgrounds, including activities of daily living (ADL) and living status, predisposing risk factors, causative agents, and severity with infectious keratitis in old (75 

Therapeutics Incorporating Blood Constituents.

Blood deficiency and dysfunctionality can result in adverse events, which can primarily be treated by transfusion of blood or the re-introduction of properly functioning sub-components. Blood constituents can be engineered on the sub-cellular (i.e., DNA recombinant technology) and cellular level (i.e., cellular hitchhiking for drug delivery) for supplementing and enhancing therapeutic efficacy, in addition to rectifying dysfunctioning mechanisms (i.e., clotting). Herein, we report the progress of blood-base...

Corneal Toxicity of Topical Tacrolimus Ointment in Mice with Corneal Epithelial Injury.

To investigate the effect of tacrolimus ointment on corneal epithelium.

Suppression of Th1-Mediated Keratoconjunctivitis Sicca by Lifitegrast.

Increased interferon gamma (IFN-γ) expression in dry eye causes ocular surface epithelial disease termed keratoconjunctivitis sicca (KCS). The purpose of this study was to investigated the effects of the LFA-1 antagonist, lifitegrast, in a mouse desiccating stress (DS) dry eye model that develops KCS similar to Sjögren syndrome.

Comparison of 0.1%, 0.18%, and 0.3% Hyaluronic Acid Eye Drops in the Treatment of Experimental Dry Eye.

To compare the efficacy of 0.1%, 0.18%, and 0.3% hyaluronic acid (HA) artificial tear in the treatment of experimental dry eye (EDE).

Impact of Flow Rate, Collection Devices, and Extraction Methods on Tear Concentrations Following Oral Administration of Doxycycline in Dogs and Cats.

Compare the precision of doxycycline quantification in tear fluid collected with either Schirmer strips or polyvinyl acetal (PVA) sponges following oral drug administration.

Mining the tree of life: Host defense peptides as antiviral therapeutics.

Discovering new therapeutics for human viral diseases is important for combatting emerging infectious viruses and omnipresent circulating viruses as well as those that can become resistant to the drugs we currently have available. The innate host defense peptide (HDP) repertoire present in animals is a wealth of potential antimicrobial agents that could be mined to meet these needs. While much of the body of research regarding HDPs is in the context of bacteria, there is increasing evidence that they can be...

PAPep Inhibits Secretion of Poly(I:C)-Induced Inflammatory Cytokines and ICAM-1 Expression in Corneal Fibroblasts by Suppressing the NF-κB/p38 Pathway.

To assess the anti-inflammatory effect and mechanism of a novel peptide, PAPep, in poly(I:C)-stimulated corneal fibroblasts.

A Novel Approach for Therapeutic Delivery to the Rodent Pancreas Via Its Arterial Blood Supply.

Endovascular techniques can now access the arterial blood supply of the pancreas in humans to enable therapeutics to reach the gland in high concentrations while concurrently avoiding issues related to non-targeted delivery. However, there is no way to replicate this in small animals. In a rat model, we therefore developed a novel non-terminal technique to deliver therapeutics to different regions of the pancreas, via its arterial blood supply.

Efficacy and Safety of Loteprednol 0.5% and Fluorometholone 0.1% After Strabismus Surgery in Children.

To compare the effects of topical loteprednol and fluorometholone in children who underwent strabismus surgery.

Development of clinical-stage human monoclonal antibodies that treat advanced Ebola virus disease in non-human primates.

For most classes of drugs rapid development of therapeutics to treat emerging infections is challenged by the timelines needed to identify compounds with the desired efficacy, safety and PK profiles. Fully human monoclonal antibodies (mAbs) provide an attractive method to overcome many of these hurdles to rapidly produce therapeutics for emerging diseases.

In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases.

In situ-based gel drug delivery systems that can bypass the blood-brain barrier, deliver the therapeutics to the desired site, reduce peripheral toxicity and control drug release kinetics have been developed. Some of the therapeutics used to treat neurological diseases suffer from poor bioavailability. Preclinical reports from several researchers have proven that the delivery of drugs to the brain via the nose-to-brain route using in situ gels holds great promise. However, safety issues on the toxicity of t...


Advertisement
Quick Search
Advertisement
Advertisement